NCT01186029

Comparison of Adding EMEND to PONV/PDNV Treatment Regimen

A Comparison Study to Determine the Increased Efficacy of Adding EMEND to the Treatment Regimen for Post-Discharge and Post-Operative Nausea and Vomiting

• Status: Withdrawn
• Phase: N/A
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: University of Nebraska · Academic / Other
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

This study is looking at whether the addition of Aprepitant (Emend), an antiemetic, will provide added efficacy if added to 2 drugs that are already used as a standard of care for post-operative nausea and vomiting and post-discharge nausea and vomiting.

Detailed description

This study is looking at whether the addition of a fairly new drug for the treatment of post-operative nausea and vomiting (PONV) and post-discharge nausea and vomiting (PDNV) will provide added efficacy if added to 2 drugs that are already used as a standard of care for PONV and PDNV. The patients that will be looked at will be deemed at higher risk for PONV and PDNV based on the procedure they are having done and/or on patient risk factors.

Conditions

• Postoperative Nausea and Vomiting

Interventions

Type	Name	Description
DRUG	aprepitant	Emend 40mg by mouth 30 minutes before procedure x 1

Timeline

• Start date: 2011-09-01
• Primary completion: 2011-09-01
• Completion: 2011-09-01
• First posted: 2010-08-20
• Last updated: 2024-08-30